State Street SPDR S&P Pharmaceuticals ETF
XPH
78 hedge funds and large institutions have $144M invested in State Street SPDR S&P Pharmaceuticals ETF in 2025 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 7 closing their positions.
183% more call options, than puts
Call options by funds: $3.41M | Put options by funds: $1.2M
129% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 7
42% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 19
13% more funds holding
Funds holding: 69 → 78 (+9)
9% more capital invested
Capital invested by funds: $132M → $144M (+$11.9M)
12.78% less ownership
Funds ownership: 75.41% → 62.63% (-13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$6.84M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$3.37M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$2.56M |
| 4 |
Jane Street
New York
|
+$1.33M |
| 5 |
LPL Financial
San Diego,
California
|
+$1.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$21M |
| 2 |
Goldman Sachs
New York
|
-$4.18M |
| 3 |
JP Morgan Chase
New York
|
-$2.65M |
| 4 |
CI
CX Institutional
Auburn,
Indiana
|
-$2.26M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.93M |
XPH Hedge Fund Activity: Q4 2025 in Review
78 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q4 2025, worth a combined $144M — up 9% from $132M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new XPH positions and 7 closed out — a net gain of 9 holders — while 27 added to existing stakes and 19 trimmed.
The largest buyer was Wells Fargo, adding an estimated $6.84M. The largest seller was Morgan Stanley, cutting an estimated $21M.
- 78 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q4 2025, up from 69 in Q3 2025.
- Funds reported $144M of State Street SPDR S&P Pharmaceuticals ETF stock for Q4 2025, up 9% quarter-over-quarter.
- 16 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q4 2025 and 7 closed out, a net change of +9 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q4 2025 was Wells Fargo, an estimated $6.84M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q4 2025 was Morgan Stanley, an estimated $21M sold.
Based on aggregated 13F filings for Q4 2025.